OS Therapies (OSTX) Net Income towards Common Stockholders (2023 - 2026)

OS Therapies (OSTX) has 4 years of Net Income towards Common Stockholders data on file, last reported at -$10.4 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 168.18% year-over-year to -$10.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$35.3 million (down 212.14% YoY) and the FY2025 annual result came in at -$28.8 million, down 222.56% from the prior year.
• Net Income towards Common Stockholders grew to -$10.4 million in Q1 2026, from -$13.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.5 million in Q1 2024 to a low of -$13.5 million in Q4 2025.
• A 4-year average of -$4.3 million and a median of -$2.9 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders soared 38.59% — and 2025, when it plunged 350.01%.
• Tracing OSTX's Net Income towards Common Stockholders over 4 years: stood at -$1.5 million in 2023, then tumbled by 99.97% to -$3.0 million in 2024, then sank by 350.01% to -$13.5 million in 2025, then climbed by 22.76% to -$10.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$10.4 million (Q1 2026), -$13.5 million (Q4 2025), and -$6.9 million (Q3 2025), per Business Quant data.